Table 3 Comparative analysis of variance (ANOVA) results
Sinopharm versus non-vaccinated | Ox-AstraZeneca versus non-vaccinated | Pfizer-BioNTech versus non-vaccinated | Ox-AstraZeneca versus Sinopharm | Pfizer-BioNTech versus Sinopharm | Pfizer-BioNTech versus Ox-AstraZeneca | |
|---|---|---|---|---|---|---|
Patients with good general health and absent co-morbidity | ||||||
F-ratio | 4.0282 | 10.8049 | 8.4404 | 2.1473 | 1.8586 | 0.003984 |
p-value | 0.04632 (Significant) | 0.001268 (Significant) | 0.004294 (Significant) | 0.146 (Non-significant) | 0.1763 (Non-significant) | 0.9499 (Non-significant) |
Effect size | 0.15 (Small) | 0.27 (Medium) | 0.25 (Medium) | 0.15 (Small) | 0.15 (Small) | 0.008 (Small) |
η2 (variance from average) | 0.023 (2.3%) | 0.069 (6.9%) | 0.059 (5.9%) | 0.021 (2.1%) | 0.021 (2.1%) | 0.000064 (0.006%) |
Tukey HSD / Tukey Kramer | Significant (× 1– × 2 | Significant (× 1– × 2) | Significant (× 1– × 2) | Non-significant | Non-significant | Non-significant |
Patients with chronic co-morbidity | ||||||
F-ratio | 0.1784 | 4.7521 | 4.1682 | 5.4522 | 6.5531 | 0.2807 |
p-value | 0.6746 (Non-significant) | 0.03492 (Significant) | 0.04857 (Significant) | 0.02667 (Significant) | 0.01751 (Significant) | 0.6035 (Non-significant) |
Effect size | 0.06 (Small) | 0.34 (Large) | 0.34 (Large) | 0.43 (Large) | 0.53 (Large) | 0.13 (Small) |
η2 (variance from average) | 0.0036 (0.04%) | 0.1 (10.2%) | 0.1 (10.4%) | 0.16 (15.8%) | 0.22 (22.2%) | 0.017 (1.7%) |
Tukey HSD / Tukey Kramer | Non-significant | Significant (× 1– × 2) | Significant (× 1– × 2) | Significant (× 1– × 2) | Significant (× 1– × 2) | Non-significant |
Immunocompromised patients | ||||||
F-ratio | 1.4856 | 11.7811 | 15.6 | 3.7143 | 5.1886 | 0.03664 |
p-value | 0.2358 (Non-significant) | 0.003177 (Significant) | 0.0009394 (Significant) | 0.07609 (Significant) | 0.03895 (Significant) | 0.8525 (Non-significant) |
Effect size | 0.26 (Medium) | 0.83 (Large) | 0.93 (Large) | 0.53 (Large) | 0.61 (Large) | 0.064 (Small) |
η2 (variance from average) | 0.063 (6.3%) | 0.41 (40.9%) | 0.46 (46.4%) | 0.22 (22.2%) | 0.27 (27%) | 0.0041 (0.4%) |
Tukey HSD / Tukey Kramer | Non-significant | Significant (× 1– × 2) | Significant (× 1– × 2) | Significant (× 1– × 2) | Significant (× 1– × 2) | Non-significant |
Globally | ||||||
F-ratio | 2.6941 | 18.5913 | 15.6817 | 8.43294 | 7.97616 | 0.1092 |
p-value | 0.102 (Non-significant) | 0.00002495 (Significant) | 0.0001055 (Significant) | 0.004262 (Significant) | 0.005499 (Significant) | 0.741812 (Non-significant) |
Tukey HSD / Tukey Kramer | Non-significant | Significant (× 1– × 2) | Significant (× 1– × 2) | Significant (× 1– × 2) | Significant (× 1– × 2) | Non-significant |